Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Atogepant Shows Efficacy for Migraine Prevention

Key clinical point: Atogepant showed safety and efficacy for migraine headache prevention in a phase 2/3 study.

Major finding: Migraine headache frequency fell by an average 3.55-4.23 days per month, compared with an average drop of 2.85 days with placebo.

Study details: A multicenter, phase 2/3 dose-ranging study with 834 U.S. patients.

Disclosures: The study was sponsored by Allergan, the company developing atogepant and ubrogepant. Dr. Dodick has been a consultant to Allergan and to several other drug companies.

Citation:

REPORTING FROM AHS 2019